Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy

  • Gerald Rosen
  • Ralph C. Marcove
  • Andrew G. Huvos
  • Brenda I. Caparros
  • Joseph M. Lane
  • Anita Nirenberg
  • Adrienne Cacavio
  • Susan Groshen
Symposium of the Cooperative Osteosarcoma Study Group — COSS 80 A Combined Diagnostic and Therapeutic Approach to Osteosarcoma Treatment May 7, 1982 in Viena

Summary

Since October 1973, 185 patients 21 years of age or younger with primary osteogenic sarcoma of an extremity were treated with adjuvant chemotherapy. Twenty-five of the first fifty-two patients (48%) have remained free of disease for a median of 7 years. In the next chemotherapy protocol most patients had chemotherapy prior to amputation or resection, during which time the dose of high-dose methotrexate was escalated in many patients to that needed to shrink the primary tumor. For a median of 4 years 43 of 54 patients (80%) have remained free of disease. In the current protocol, the response of the primary tumor to chemotherapy with high-dose methotrexate was used to select postoperative adjuvant chemotherapy for the patient. With the latter approach 73 of 79 patients (92%) have remained continuously free of disease for a median of 2 years. This experience demonstrates the value of chemotherapy in increasing the cure rate in osteogenic sarcoma and that the response to preoperative chemotherapy can help select postoperative chemotherapy to produce an even higher potential cure rate for osteogenic sarcoma.

Key words

Osteogenic sarcoma Chemotherapy Hig-dose methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allen JC, Rosen G, Mehta B, Horten B (1980) Leukoencephalopathy following high dose I. V. methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64:1261–1273Google Scholar
  2. 2.
    Burchenal J (1975) From wild fowl to stalking horses: Alchemy in chemotherapy. Cancer 35:1121–1135Google Scholar
  3. 3.
    Catane R, Bono VH, Louie AC (1978) High-dose methotrexate, not a conventional treatment. Cancer Treat Rep 62:178–180Google Scholar
  4. 4.
    Cortes EP, Holland JF, Wang JJ (1975) Adriamycin (NSC-123127) in 87 patients with osteogenic sarcoma. Cancer Chemother Rep (part 3) 6:305–313Google Scholar
  5. 5.
    Etcubanas E, Wilbur JR (1978) Adjuvant chemotherapy for osteogenic sarcoma. Cancer Treat Rep 62:283–287Google Scholar
  6. 6.
    Fossati-Bellani F, Gasparini M, Gennari L (1978) Adjuvant treatment with adriamycin in primary operable osteosarcoma. Cancer Treat Rep 62:289–294Google Scholar
  7. 7.
    Friedman MA, Carter SK (1972) The therapy of osteogenic sarcoma. Current status and thoughts for the future. J Surg Oncol 4:482–510Google Scholar
  8. 8.
    Jaffe N (1972) Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30:1627–1631Google Scholar
  9. 9.
    Jaffe N, Frei E, Traggis D (1977) Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma. Cancer 39:45–50Google Scholar
  10. 10.
    Marcove RC, Mike V, Hajek JV (1970) Osteogenic sarcoma under the age of 21. A review of 145 operative cases. J Bone Joint Surg [Am] 52:411–423Google Scholar
  11. 11.
    Marcove RC, Mike V, Hajek JV (1977) Osteogenic sarcoma in childhood. New York State J Med 71:855–859Google Scholar
  12. 12.
    Marcove RC (1977) En bloc resection for osteogenic sarcoma. Can J Surg 20:521–528Google Scholar
  13. 13.
    Marcove RC, Lewis MM, Huvos AG (1977) En bloc upper humeral interscapulo-thoracic resection. The Tikhoff-Linberg procedure. Clin Orthop 124:219–228Google Scholar
  14. 14.
    Mehta BM, Juergens H, Allen JC (1980) Distribution of methotrexate, citrovorum factor, and 5-methyltetrahydrofolate after high-dose methotrexate-leucovorin recue in osteogenic sarcoma. In: Nelson JD, Grassi C (eds) Current chemo-therapy and infectious disease. Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington D.C. (vol 22, pp 1535–1636)Google Scholar
  15. 15.
    Mosende C, Guttierez M, Caparros B (1977) Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer 40:2779–2786Google Scholar
  16. 16.
    Nirenberg A, Mosende C, Mehta BM (1977) High dose methotrexate with citrovorum factor rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 61:779–783Google Scholar
  17. 17.
    Ochs JJ, Freeman AI, Douglass HO (1978) Cis-dichlorodiammine-platinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62:239–245Google Scholar
  18. 18.
    Pratt CB, Howarth C, Ranson JL (1980) High-dose methotrexate alone and in combination therapy for measurable primary or metastatic osteosarcoma. Cancer Treat Rep 64:11–20Google Scholar
  19. 19.
    Pratt CB (1980) Chemotherapy of osteosarcoma. An overview. In: Van Oosterom AT, Muggia FM, Cleton FJ (eds) Therapeutic progress in ovarian cancer, testicular cancer and the sarcomas. Martinus Nijhoff, The Hague (pp. 329–348)Google Scholar
  20. 20.
    Pratt CB, Shanks EC, Hustu HO (1977) Adjuvant multiple drug chemotherapy for osteogenic sarcoma of the extremity. Cancer 39:51–57Google Scholar
  21. 21.
    Rosen G, Murphy ML, Huvos AG (1976) Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37:1–11Google Scholar
  22. 22.
    Rosen G, Huvos AG, Mosende C (1978) Chemotherapy and thoracotomy for metastatic osteogenic sarcoma. A model for adjuvant chemotherapy and the rationale for the timing of thoracic surgery. Cancer 41:841–849Google Scholar
  23. 23.
    Rosen G, Nirenberg A, Juergens H (1980) Response of primary osteogenic sarcoma to single-agent therapy with high-dose methotrexate und citrovorum factor rescue. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious disease. Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington D.C. (vol. 2, pp. 1633–1635)Google Scholar
  24. 24.
    Rosen G, Marcove RC, Caparros B (1979) Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163–2177Google Scholar
  25. 25.
    Rosen G, Nirenberg A, Juergens H (1979) Phase II trial of cisplatinum in osteogenic sarcoma. Proc Am Assoc Cancer Res 20:363Google Scholar
  26. 26.
    Rosen G, Suvanisirikul S, Kwon C (1974) High-dose Methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer 33:1151–1163Google Scholar
  27. 27.
    Rosen G, Caparros B, Huvos AG (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based upon the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230Google Scholar
  28. 28.
    Rosenberg SA, Chabner BA, Young RC (1979) Treatment of osteogenic sarcoma. Effect of adjuvant high-dose Methotrexate after amputation. Cancer Treat Rep 63:739–751Google Scholar
  29. 29.
    Rosenberg SA, Flye MW, Conkle D (1979) Treatment of osteogenic sarcoma. Aggressive resection of pulmonary metastases. Cancer Treat Rep 63:753–756Google Scholar
  30. 30.
    Salzer M, Knahr K, Kotz R, Kristen H (1981) Treatment of osteosarcomata of the distal femur by rotation-plasty. Arch Orthop Traumat Surg 99:131–136Google Scholar
  31. 31.
    Sutow WW, Vietti TJ, Fernbach DJ (1971) Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma. Cancer Chemother Rep 55:67–81Google Scholar
  32. 32.
    Sutow WW, Gehan EA, Dyment PA (1978) Multi-drug adjuvant chemotherapy for osteosarcoma. Interim Report of the Southwest Oncology Group Studies. Cancer Treat Rep 62:265–270Google Scholar
  33. 33.
    Sutow WW, Sullivan MP, Milbur JR (1975) A study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol 7:530–533Google Scholar
  34. 34.
    Van Ness CP (1950) Rotationplasty in the treatment of congenital defects of the femur. J Bone Joint Surg [Br] 32:12Google Scholar
  35. 35.
    Weinfeld MS, Dudley HR (1962) Osteogenic sarcoma. A followup study of 94 cases observed at the Massachusetts General Hospital from 1920 to 1960. J Bone Joint Surg [Am] 44:269–276Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Gerald Rosen
    • 1
    • 2
  • Ralph C. Marcove
    • 3
  • Andrew G. Huvos
    • 4
  • Brenda I. Caparros
    • 1
  • Joseph M. Lane
    • 3
  • Anita Nirenberg
    • 1
    • 5
  • Adrienne Cacavio
    • 5
  • Susan Groshen
    • 6
  1. 1.The Department of PediatricsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.The Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.The Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  4. 4.The Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  5. 5.The Department of NursingMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  6. 6.The Department of BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations